Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ 2,196	$ (99,120)	$ (80,716)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Loss from Equity Method Investment in the Joint Venture			104,497
Depreciation and amortization	151,143	436,552
Amortization of capitalized software developed for sale	460	550
Accretion and changes in estimate, net	(2,759)	8,429
Equity compensation		34,858
Deferred income tax expense (benefit)		(33,905)	(564)
Amortization of debt discount and issuance costs		24,587	403
Contingent consideration		(3,000)
Gain on sale of businesses	(32,217)	(60,487)
Loss on extinguishment of debt	6,145	7,634
(Gain) loss on forward purchase contract			(71,649)
Non-cash lease expense		21,930
Other, net		7,681	1,526
Changes in operating assets and liabilities:
Accounts receivable, net		28,331
Contract assets, net		5,201
Prepaid expenses and other		(69,609)	(1,335)
Accounts payable		(15,785)
Accrued expenses and other liabilities		68,708	47,255
Deferred revenue		124,679
Due to the Joint Venture, net			583
Net cash provided by (used in) operating activities		487,234
Cash flows from investing activities:
Capitalized expenditures		(182,929)
Acquisitions, net of cash acquired		(439,483)
Proceeds from sale of businesses		117,124
Investment in the Joint Venture			(610,784)
Investment in debt and equity securities of the Joint Venture			(278,875)
Other, net		1,100	7,332
Net cash provided by (used in) investing activities		(504,188)	(882,327)
Cash flows from financing activities:
Payments on Revolving Facility		(250,000)
Payments on Term Loan Facility		(265,000)
Proceeds from issuance of Senior Notes		325,000
Payments under tax receivable agreements		(20,691)
Receipts (payments) on derivative instruments		(22,255)
Employee tax withholding on vesting of equity compensation awards		(3,425)
Payments on deferred financing obligations		(9,081)
Payment of senior amortizing notes		(11,599)	(7,332)
Proceeds from exercise of equity awards		4,158	2,105
Proceeds from initial public offering, net of issuance costs			608,679
Proceeds from issuance of equity component of tangible equity units, net of issuance costs			232,929
Proceeds from issuance of debt component of tangible equity units			47,367
Other, net		(6,650)	(1,421)
Net cash provided by (used in) financing activities		(259,543)	882,327
Effect of exchange rate changes on cash and cash equivalents		3,449
Net increase (decrease) in cash and cash equivalents		(273,048)
Cash and cash equivalents at beginning of period		410,405	3,409
Cash and cash equivalents at end of period	$ 137,357	$ 137,357	$ 3,409